2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1380

Complications Following Total Hip Arthroplasty in Inflammatory Versus Osteoarthritis
Abstract Number: 1932

Complications Following Total Knee Arthroplasty in Inflammatory Versus Osteoarthritis
Abstract Number: 332

Components of Impaired Physical Function and Disability in a Non-Rheumatic Population. Normative Values of the Health Assessment Questionnaire Disability Index
Abstract Number: 16

Comprehensive Antibody Profiling Using High Density Peptide Arrays Reveals Novel Citrullinated Protein Targets in Rheumatoid Arthritis Serum Samples
Abstract Number: 1980

Comprehensive Association Analysis between Rare and Common ABCG2 Variants and Gout Susceptibility
Abstract Number: 2871

Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1043

Computational Analysis of Potential Self-Antigens in Osteoarthritis
Abstract Number: 2888

Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Abstract Number: 1667

Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales
Abstract Number: 1073

Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis
Abstract Number: 1193

Consensus Statements on Scanning Conventions and Documentation in Musculoskeletal Ultrasound
Abstract Number: 658

Construct Validation of the Screening for Inflammatory Pain in the Lower Back Questionnaire: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
Abstract Number: 2222

Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Abstract Number: 641

Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis
Abstract Number: 849

Constructing a Macrophage Infiltration Timeline in a Murine Model of Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].